Deutsche Bank Analysts Give AstraZeneca (LON:AZN) a GBX 6,800 Price Target

Deutsche Bank set a GBX 6,800 ($88.85) price objective on AstraZeneca (LON:AZN) in a research report sent to investors on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. Liberum Capital restated a hold rating on shares of AstraZeneca in a research note on Friday, March 29th. Shore Capital restated a buy rating on shares of AstraZeneca in a research note on Monday, February 25th. Bryan, Garnier & Co restated a neutral rating on shares of AstraZeneca in a research note on Friday, March 29th. Barclays set a GBX 6,800 ($88.85) target price on AstraZeneca and gave the stock a buy rating in a research note on Monday, February 25th. Finally, HSBC set a GBX 5,140 ($67.16) target price on AstraZeneca and gave the stock a sell rating in a research note on Thursday, February 28th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of GBX 6,497.06 ($84.90).

Shares of LON AZN opened at GBX 6,365 ($83.17) on Monday. AstraZeneca has a 52 week low of GBX 5,110 ($66.77) and a 52 week high of GBX 6,545 ($85.52). The business has a 50-day moving average of GBX 6,039.80. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. The company has a market cap of $83.49 billion and a P/E ratio of 33.50.

In other news, insider Marc Dunoyer bought 8,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The stock was bought at an average price of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley bought 520 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was purchased at an average price of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.